Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp307 | Osteoporosis: treatment | ECTS2014

Effect of daily intake of milk enriched with a high dose of vitamin D in healthy postmenopausal women: preliminary results from a randomized, controlled and double-blind nutritional trial (The EFICALCIO study)

Munoz-Torres Manuel , Reyes-Garcia Rebeca , Garcia-Martin Antonia , Palacios Santiago , Salas Nancy , Mendoza Nicolas , Quesada-Charneco Miguel , Fonolla Juristo

Background: Vitamin D deficiency is highly prevalent and can be associated with adverse health outcomes. Few studies have evaluated the effects of daily consumption of milk fortified with a high dose of vitamin D in a large cohort of healthy postmenopausal women.Objectives: To determine the effect of daily intake of milk enriched with vitamin D (with or without fructooligosaccharides (FOS)) on vitamin D status, bone mass and cardiovascular risk factors.<...

ba0001pp446 | Osteoporosis: treatment | ECTS2013

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate– a randomized placebo-controlled trial

Chapurlat Roland , De Villiers Tobias , Bonnick Sydney , Odio Alberto , Palacios Santiago , Scott Boyd , De Tilleghem Celine Le Bailly , DaSilva Carolyn , Leung Albert , Gurner Deborah

Odanacatib (ODN) is an orally-active cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This study evaluated the effects of ODN 50mg once weekly on BMD, bone turnover markers and safety in patients previously treated with alendronate (ALN).This was a randomized, double-blind, placebo-controlled, 24-month study. The primary endpoint was % change from baseline at month 24 of femoral neck (FN) BMD. Postmenopausal women (...